WO2021153785A1 - コラーゲン産生能の維持または促進剤 - Google Patents

コラーゲン産生能の維持または促進剤 Download PDF

Info

Publication number
WO2021153785A1
WO2021153785A1 PCT/JP2021/003393 JP2021003393W WO2021153785A1 WO 2021153785 A1 WO2021153785 A1 WO 2021153785A1 JP 2021003393 W JP2021003393 W JP 2021003393W WO 2021153785 A1 WO2021153785 A1 WO 2021153785A1
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
maintaining
producing ability
vitamin
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/003393
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
宮沢　和之
レノ ジレ
ビアンカ マッカーシー
哲也 金丸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to CN202180011924.XA priority Critical patent/CN115003269A/zh
Priority to JP2021574727A priority patent/JPWO2021153785A1/ja
Priority to US17/796,577 priority patent/US20230052667A1/en
Publication of WO2021153785A1 publication Critical patent/WO2021153785A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Definitions

  • the present invention relates to a collagen-producing ability-maintaining or promoting agent of a cell containing a wavelength-converting substance, a composition and a product containing a collagen-producing ability of such a cell, and a collagen production of a skin cell using them. Concerning methods for maintaining or promoting performance.
  • the skin is exposed daily to various physical and chemical stresses such as ultraviolet rays, dryness, cold, heat, and drugs.
  • the harmful effects of ultraviolet rays on the skin include, for example, skin cancer, photoaging, age spots, wrinkles, and inflammation, which are not preferable from the viewpoint of health and beauty.
  • ultraviolet rays for the purpose of bactericidal effect, considering the balance with the harmful effects of ultraviolet rays, the focus is on protecting them rather than actively using them. The current situation.
  • UV-cut film Therefore, many measures have been taken to protect the skin from UV rays. For example, the use of sunscreen, indoor activities that are not exposed to sunlight, UV-cut hats and clothing, and the use of UV-cut film.
  • An object of the present invention is to maintain and / or provide a novel cell collagen-producing ability using ultraviolet rays.
  • the present inventors have conducted diligent research so that ultraviolet rays can be effectively used for the skin. As a result, we changed the wavelength of ultraviolet rays and came up with a collagen production promoter for skin cells.
  • the present application provides the following inventions.
  • the wavelength conversion substance is a collagen-producing ability-maintaining or promoting agent that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • the collagen-producing ability maintaining or promoting agent according to (1) or (2), wherein the emitted light has a peak wavelength in the range of 450 nm to 700 nm.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • One or more phycocyanin proteins selected from zinc oxide phosphors, magnesium titanate phosphors, and calcium phosphate phosphors; vitamin A, ⁇ -carotenoids, vitamin K, vitamins Selected from B1, Vitamin B2, Vitamin B6, Vitamin B12, Folic Acid, Niacin, Lycopine, Cutinashi, Benibana, Ukon, Cochinil, Perilla, Red Cabbage, Flavonoids, Carotenoids, Kinoids, Porphyrins, Anthocyanins, and Polyphenols 1 Species or multiple components; and / or Red 401, Red 227, Red 504, Red 218, Orange 205 P, Yellow 4, Yellow 5, Green 201, Phycocyanin Conch, Blue 1, Selected from 2,4-diaminophenoxyethanol hydrochloride, Arizulin purple SS, purple 401, black 401, herringdon pink, yellow 401, phycocyanin yellow G, blue 404, red 104, and metaamin
  • the agent for maintaining or promoting the collagen-producing ability according to any one of (1) to (3), which comprises one or more kinds of pigments.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • One or more phycoerythrinth proteins one or more inorganic phosphors selected from zinc oxide phosphors, magnesium titanate phosphors, and calcium phosphate phosphors; and / or vitamin B1, vitamin B2,
  • the agent for maintaining or promoting the collagen-producing ability according to (4) which comprises one or more kinds of vitamin B selected from vitamin B6 and vitamin B12.
  • the composition according to (6), wherein the composition is a composition for external use on the skin and is for maintaining or promoting the collagen-producing ability of cells under irradiation with light including ultraviolet rays.
  • the present invention can exert a favorable effect on the skin by maintaining or promoting the collagen-producing ability of skin cells while being exposed to ultraviolet rays.
  • ultraviolet rays are not preferable for the skin, and in particular, they reduce the collagen-producing ability of skin cells and promote the decomposition of collagen itself, which may cause wrinkles and prevent the skin from being exposed to ultraviolet rays as much as possible. It is the common technical knowledge in this field to adopt.
  • the present invention is very surprising because it is based on the finding that preferable functions such as collagen-producing ability of skin cells are maintained and promoted even when exposed to ultraviolet rays.
  • the present invention also provides new uses for the above-mentioned compounds that have been conventionally mainly used as pigments, pigments, ultraviolet scattering agents, ultraviolet absorbers, nutritional components, antioxidants, and the like. Further, the present invention may lead to improvement of quality of life such that even a person who has avoided ultraviolet rays as much as possible for beauty and health reasons can feel like going out positively.
  • the collagen-producing ability-maintaining or promoting agent of the present invention contains a wavelength-converting substance as an active ingredient.
  • the wavelength conversion substance refers to a substance that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • Ultraviolet rays may include UVA, UVB, UVC and the like.
  • ultraviolet light is light having a peak wavelength between 200 nm and 400 nm.
  • the incident light such as sunlight may contain ultraviolet rays.
  • the incident light may be ultraviolet rays, or artificially generated ultraviolet rays may be used.
  • the emitted light emitted by the wavelength converting substance has a longer wavelength than ultraviolet rays, and has a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the emitted light is, for example, but not limited to, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, It may have one or more peaks in 650nm, 660nm, 670nm, 680nm, 690nm, 700nm, or any range of these values, or in red light, orange light, green light, blue light, etc.
  • the wavelength-converting material exhibits a main wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm, of light emitted when excited by excitation light of 200 nm to 400 nm.
  • wavelength converters include: allophicocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phy Phycoerythrin and other phycocyanins; vitamin A, ⁇ -carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, lycopene, cutinashi, benibana, turmeric, cochineal, perilla, red cabbage, flavonoids, carotenoids , Kinoids, porphyrins, anthocyanins, polyphenols, etc.
  • Red 401, Red 227, Red 504, Red 218, Orange 205 P Yellow 4, Yellow 5, Green 201 No., Pyranin Conc, Blue No. 1, Hydrochloride 2,4-diaminophenoxyethanol, Arizulin Purple SS, Purple No. 401, Black No. 401, Herringdon Pink, Yellow No. 401, Benchin Yellow G, Blue No. 404, Red No. 104, Dyes such as metaaminophenol; phosphors doped with inorganic compounds to have fluorescence, for example, blue phosphors containing the amorphous silica particles described in Patent No. 6424656, cerium, phosphorus and / or magnesium.
  • a red phosphor containing a compound in which europium is activated in a mixed crystal of alkaline earth metal sulfide and gallium compound described in Patent No. 6361416 zinc oxide phosphor described in International Publication No. 2018/004006, special feature.
  • Examples thereof include the zinc oxide phosphor described in Kai 2018-131422; the inorganic phosphor described in JP-A-5-117127; and the like.
  • the inorganic phosphor can represent zinc oxide as ZnO: Zn, Zn 1 + z , ZnO 1-x , as described in WO 2018/004006, eg, zinc sulfide, zinc sulfate.
  • the wavelength conversion substance may be obtained from natural products such as animals, plants, and algae by a method such as extraction, or may be obtained by an artificial method such as chemical synthesis.
  • the phycobiliprotein is algae such as blue-green algae such as Spirulina platensis and red algae such as Porphyridium purpureum. It may be prepared by extraction.
  • the zinc oxide phosphor may be produced, for example, by the methods described in International Publication No. 2018/004006, JP-A-2018-131422, and JP-A-5-117127.
  • the magnesium titanate phosphor may be produced by the method described in JP-A-2017-88719.
  • the calcium phosphate phosphor may be produced by the method described in WO 2018/117117.
  • wavelength conversion substances may be composed of the components exemplified above, may be contained, or may be used alone or in combination of a plurality of types, as long as the wavelength conversion effect of the present invention is not impaired. good.
  • other wavelength converting substances such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.) may be mixed with the phycobiliprotein or the inorganic phosphor to aim for a synergistic effect.
  • these components are examples, and any substance exhibiting the wavelength conversion effect of the present invention can be used.
  • the content of the wavelength converting substance in the maintaining or promoting agent, composition or product of the collagen producing ability of the present invention is not particularly limited as long as the wavelength converting effect of the present invention is not impaired, and the type of the wavelength converting substance and the collagen producing ability are not particularly limited. Can be appropriately determined depending on the maintenance or use of the accelerator or composition. For example, it is arbitrary within the range of 0.01 to 99.99% by weight, 0.1% to 999% by weight, and the like.
  • the collagen-producing ability-maintaining or promoting agent of the present invention has an excellent collagen-producing ability maintaining or promoting action, such as prevention of aging of human skin, retention of skin elasticity and elasticity, prevention / treatment of arthritis, etc., initial treatment of burns, etc. It is effectively used for.
  • it can be applied to external preparations for skin that indicate that fact.
  • the measurement of collagen-producing ability may be performed by a well-known method and is not particularly limited, but 3,4-DHPAA is N-terminal, for example, as in the collagen quantification kit of Cosmo Bio Co., Ltd. described in Examples. It can be measured by utilizing the fact that it selectively binds to a peptide having glycine and emits fluorescence.
  • Collagen constituting the skin includes type I, type III, type IV, type V, type XII, type XIV, etc., and is not particularly limited in the present invention, but is preferably type I.
  • the administration form of the collagen-producing ability of the present invention is arbitrary, but in order to maintain or promote the collagen-producing ability of skin cells while exposing the skin to light containing ultraviolet rays, pharmaceuticals and quasi-drugs are used. External skin preparations such as products and cosmetics may be preferable.
  • the dosage form, application method, number of administrations and the like can be arbitrarily determined. For example, in the form of lotion, spray, oil, cream, milky lotion, gel, sunscreen, suntan, etc., regularly or irregularly, for example, once to several times a day, such as in the morning, noon, and evening. It may be applied to the skin each time before going out, outdoor activities, marine sports, skiing, etc. before being expected to be exposed to the sun.
  • the collagen-producing ability-maintaining or promoting agent and composition of the present invention may be used, for example, as an excipient, a preservative, a thickener, a binder, a disintegrant, a dispersant, a stabilizer, and a gel.
  • Agents, antioxidants, surfactants, preservatives, oils, powders, water, alcohols, thickeners, chelating agents, silicones, antioxidants, moisturizers, fragrances, various medicinal ingredients, preservatives, pH Additives such as regulators and neutralizers can be arbitrarily selected and used in combination.
  • other cell activators and the like may be used in combination.
  • the present invention contains the collagen-producing ability of the present invention, and for maintaining or promoting the collagen-producing ability of skin cells while the skin is exposed to light including ultraviolet rays, for example, a sun visor, a hat.
  • light including ultraviolet rays, for example, a sun visor, a hat.
  • products such as clothing, gloves, screen films, window sprays and creams, window materials, and wall materials. Similar to the above, the use of additives and the like in the product of the present invention and the form of the product are also arbitrary.
  • the present invention also provides a method for producing a collagen-producing ability-maintaining or promoting agent, composition or product of the present invention. It also provides a method for maintaining or promoting the collagen-producing ability of a subject's skin cells, wherein the method applies the maintaining or promoting agent or composition of the collagen-producing ability of the present invention to the subject's skin. That, and the skin after application of the collagen-producing ability or accelerator or composition is exposed to light containing ultraviolet rays; or the product of the present invention is allowed to pass light containing ultraviolet rays, and the passing light.
  • the collagen-producing ability-maintaining or promoting agent, composition and product may convert the wavelength of ultraviolet rays contained in the incident light to emit light having a wavelength longer than the wavelength of the ultraviolet rays. Is emitted, and ultraviolet rays having a peak wavelength of preferably 200 nm to 400 nm are passed through as light having a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the present invention also provides a method for promoting the collagen-producing ability of a subject skin cell, wherein the method applies the collagen-producing ability promoter or composition of the present invention to the subject skin.
  • the collagen-producing ability-maintaining or promoting agent, composition and product including exposure to the skin; convert the wavelength of the ultraviolet rays contained in the incident light to emit emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • An ultraviolet ray having a peak wavelength of 200 nm to 400 nm is preferably passed as light having a peak wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm, and a wavelength converter preferably magnesium titanate and / or Contains C-phycocyanin.
  • the methods for maintaining or promoting the collagen-producing ability of the cells of the subject's skin are for cosmetic purposes and may not be the therapeutic methods used by doctors and healthcare professionals.
  • the present invention also provides a cosmetological method of the present invention, a cosmetological counseling method for supporting a cosmetological act of a subject, including presenting the cosmetological method, a collagen-producing ability maintaining or promoting agent, a composition or a product to the subject.
  • the wavelength conversion material was prepared as follows.
  • Lumate G is a zinc oxide phosphor obtained by doping ZnO with a sulfur-containing compound and then firing it as described in International Publication No. 2018/004006.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum peaks at 510 nm. Had a wavelength.
  • Magnesium titanate phosphor Lumate R manufactured by Sakai Chemical Industry Co., Ltd. was used.
  • Lumate R is a magnesium titanate phosphor doped with MgTiO 3 with manganese.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum has a peak wavelength in the band of 660 to 680 nm.
  • (3) C-Phycocyanin C-phycocyanin is obtained from Spirulina platensis extract, the absorption spectrum has a peak wavelength at 350 nm, and the emission spectrum has a peak wavelength at 640 nm and 700 nm. Was there.
  • the left half of the 2nd to 5th plates was covered with an aluminum seal.
  • the lid was placed on the lid of the cultured 6-well plate, and in the third sheet, the zinc oxide phosphor film was placed on the cultured plate, and an unused lid was placed.
  • the fourth sheet was covered with a magnesium titanate phosphor film, and a lid was placed on it.
  • a plate containing a 2 mL / well aqueous solution of C-phycocyanin was placed on the cultured plate with the lid removed. At this time, the artificial solar light passed through the phosphor film and was irradiated to the cell solution without the phosphor film coming into direct contact with the cell solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2021/003393 2020-01-31 2021-01-29 コラーゲン産生能の維持または促進剤 Ceased WO2021153785A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202180011924.XA CN115003269A (zh) 2020-01-31 2021-01-29 胶原产生能力的维持或促进剂
JP2021574727A JPWO2021153785A1 (https=) 2020-01-31 2021-01-29
US17/796,577 US20230052667A1 (en) 2020-01-31 2021-01-29 Agent for maintaining or enhancing collagen production ability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020015714 2020-01-31
JP2020-015714 2020-01-31

Publications (1)

Publication Number Publication Date
WO2021153785A1 true WO2021153785A1 (ja) 2021-08-05

Family

ID=77078909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/003393 Ceased WO2021153785A1 (ja) 2020-01-31 2021-01-29 コラーゲン産生能の維持または促進剤

Country Status (4)

Country Link
US (1) US20230052667A1 (https=)
JP (1) JPWO2021153785A1 (https=)
CN (1) CN115003269A (https=)
WO (1) WO2021153785A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024005536A (ja) * 2022-06-30 2024-01-17 ライオン株式会社 スキンケアセット及びコラーゲン産生促進方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117127A (ja) * 1991-10-02 1993-05-14 Shiseido Co Ltd 蛍光化粧料
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2016500052A (ja) * 2012-09-20 2016-01-07 エコシステム フィコシアニンを抽出および安定化する方法とその利用
JP2017036277A (ja) * 2015-08-13 2017-02-16 ヤー チュン ション チー ユー シエン コン スー 美容用シート
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
WO2017142057A1 (ja) * 2016-02-18 2017-08-24 ロート製薬株式会社 皮膚外用組成物
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB639086A (en) * 1947-01-17 1950-06-21 British Thomson Houston Co Ltd Improvements in and relating to magnesium titanate phosphors
JP2000219607A (ja) * 1999-01-28 2000-08-08 Shiseido Co Ltd 外用組成物
EP1470824A1 (en) * 2002-12-10 2004-10-27 L-MAbs B.V. Affinity proteins for controlled application of cosmetic substances
ES2998457T3 (en) * 2003-11-21 2025-02-20 Nestle Sa Food composition comprising glucosamine
FR2885520B1 (fr) * 2005-05-10 2007-10-05 Oreal Composition cosmetique
US8088570B2 (en) * 2006-04-18 2012-01-03 Kao Corporation Method for screening an agent for preventing or ameliorating wrinkles
FR2918876B1 (fr) * 2007-07-16 2012-10-05 Oreal Utilisation de lumiere verte pour activer la l-amino acide oxydase
EP2710996B1 (en) * 2007-12-14 2022-08-17 Basf Se Sunscreen compositions comprising colour pigments
JP2009209093A (ja) * 2008-03-04 2009-09-17 Shiseido Co Ltd 皮膚バリアー機能回復促進剤及び皮膚外用剤
JP2012250968A (ja) * 2011-06-01 2012-12-20 Momotani Juntendo:Kk マトリックスメタロプロテアーゼ−１産生抑制剤及び／又はコラーゲン産生促進剤
US11312902B2 (en) * 2016-06-30 2022-04-26 Sakai Chemical Industry Co., Ltd. Zinc oxide phosphor and method for producing same
JP6608874B2 (ja) * 2017-06-15 2019-11-20 株式会社東洋新薬 美容組成物
TR201711917A2 (tr) * 2017-08-11 2019-02-21 Dokuz Eyluel Ueniversitesi Rektoerluegue Uv işiği kirmizi işiğa dönüştüren fosfor bazli güneş koruyucu
JP7234510B2 (ja) * 2017-11-29 2023-03-08 堺化学工業株式会社 化粧料
CN113747875A (zh) * 2019-04-05 2021-12-03 株式会社资生堂 含有紫外线波长转换物质的组合物
WO2020204189A1 (ja) * 2019-04-05 2020-10-08 株式会社 資生堂 紫外線波長変換物質を含有する水中油型乳化組成物
WO2020202764A1 (ja) * 2019-04-05 2020-10-08 株式会社 資生堂 細胞賦活剤
EP3950000A4 (en) * 2019-04-05 2023-05-03 Shiseido Company, Ltd. EMULSION COMPOSITION WITH A SUBSTANCE FOR TRANSFORMING ULTRAVIOLET WAVELENGTHS AND AN ORGANIC OIL PHASE THICKENER
JP2020183356A (ja) * 2019-05-08 2020-11-12 Dic株式会社 フィコシアニンを有効成分として含有することを特徴とする化粧料

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117127A (ja) * 1991-10-02 1993-05-14 Shiseido Co Ltd 蛍光化粧料
JP2016500052A (ja) * 2012-09-20 2016-01-07 エコシステム フィコシアニンを抽出および安定化する方法とその利用
JP2017036277A (ja) * 2015-08-13 2017-02-16 ヤー チュン ション チー ユー シエン コン スー 美容用シート
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
WO2017142057A1 (ja) * 2016-02-18 2017-08-24 ロート製薬株式会社 皮膚外用組成物
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATO, TOSHIMITSU: "1. What is Spirulina blue colorant?", NEW FOOD INDUSTRY, vol. 29, no. 3, 1987, pages 17 - 21 *
LUMATE: "Shining new cosmetic raw material, Inorganic fluorescent powder Lumate@ series", FRAGRANCE JOURNAL, July 2015 (2015-07-01), pages 62 - 63 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024005536A (ja) * 2022-06-30 2024-01-17 ライオン株式会社 スキンケアセット及びコラーゲン産生促進方法
JP7843656B2 (ja) 2022-06-30 2026-04-10 ライオン株式会社 コラーゲン産生促進方法

Also Published As

Publication number Publication date
US20230052667A1 (en) 2023-02-16
CN115003269A (zh) 2022-09-02
JPWO2021153785A1 (https=) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7569308B2 (ja) 細胞賦活剤
WO2020204193A9 (ja) 紫外線波長変換物質を含有する組成物
KR20220059822A (ko) 자외선 및 블루라이트 차단용 화장료 조성물
WO2021153785A1 (ja) コラーゲン産生能の維持または促進剤
WO2021153773A1 (ja) 光老化抑制剤
JP2024031642A (ja) 可視光によりリボフラビンの生理作用を増強するための美容方法
WO2021153771A1 (ja) ヒアルロン酸産生促進剤
WO2021153781A1 (ja) コラーゲン糖化抑制剤
JP7773378B2 (ja) 皮膚バリア機能亢進剤
WO2021153776A1 (ja) 血管新生抑制剤
CN116999342A (zh) 一种化妆品组合物
JP2021107369A (ja) 紫外線波長変換物質を含有する組成物
WO2021153780A1 (ja) 抗酸化剤又は皮膚ストレス抑制剤
WO2021153783A1 (ja) 炎症抑制剤
WO2024232264A1 (ja) 光応答性抗酸化剤の抗酸化作用を増強するための美容方法
JP7509541B2 (ja) 紫外線波長変換物質及び有機系油相増粘剤を含有する乳化組成物
JP2024031635A (ja) 可視光によりフラボノイドの生理作用を増強するための美容方法
CN119630383A (zh) 光调制性化妆品组合物及其用途
JP2024164571A (ja) 皮脂産生抑制剤
CN118546257A (zh) 一种抗光老化多重能量共振融合蛋白及其制备方法和应用
JP2021107367A (ja) 紫外線波長変換物質を含有する水中油型乳化組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21748311

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021574727

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21748311

Country of ref document: EP

Kind code of ref document: A1